Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine
To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation. We assessed the relationship...
Gespeichert in:
| Veröffentlicht in: | PharmacoEconomics 2000-04, Vol.17 (4), p.351-360 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 360 |
|---|---|
| container_issue | 4 |
| container_start_page | 351 |
| container_title | PharmacoEconomics |
| container_volume | 17 |
| creator | Hauber, A B Gnanasakthy, A Snyder, E H Bala, M V Richter, A Mauskopf, J A |
| description | To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation.
We assessed the relationship between Mini-Mental State Examination (MMSE) score and institutionalisation using a piecewise Cox proportional hazard model. To estimate cost savings from treatments lasting 6 months, 1 year and 2 years, estimates of the probability of institutionalisation were integrated with data from two 6-month phase III clinical trials of rivastigmine and a hazard model of disease progression.
Our data suggest that savings in the overall cost of caring for patients with mild and moderate AD can be as high as $US4839 per patient after 2 years of treatment. Furthermore, the probability of institutionalisation increases steadily as MMSE score falls. Among our study individuals, age, race, level of education and marital status were significant predictors of institutionalisation, whereas gender had little effect.
Using rivastigmine to treat AD results in a delay in disease progression for patients who begin treatment during the mild or moderate stages of the disease. By delaying the probability that a patient will be institutionalised, the cost of caring for AD patients can be significantly reduced. |
| doi_str_mv | 10.2165/00019053-200017040-00005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_repec</sourceid><recordid>TN_cdi_proquest_miscellaneous_71222395</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71222395</sourcerecordid><originalsourceid>FETCH-LOGICAL-p305t-bcd1d06d8cb35e85b90f7479fb31c6c1bc37b3accfbd577589d2266e139dd1f53</originalsourceid><addsrcrecordid>eNo9UEtLAzEYDKJoffwFyUlPq3lsNs1Rik8EPdSbsGSTb7vRfZmkLfrrTbV6mG-GYZgPBiFMyQWjhbgkhFBFBM_YRkmSkywJInbQhFKpks3k7o8mmSwUOUCHIbylRMEl20cHlKhc5opM0OvzEKGPTrc46JXrFwG7HscGsBlCxEONjfbJxvXg8VX71YDrwJ8HbF0AHeACzz3o2KUOvHaxwd6tdIhu0bkejtFerdsAJ1s-Qi831_PZXfb4dHs_u3rMRk5EzCpjqSWFnZqKC5iKSpFa5lLVFaemMLQyXFZcG1NXVkgppsoyVhRAubKW1oIfobPf3tEPH0sIsexcMNC2uodhGUpJGWNcbYIPv0EPI5hy9K7T_rNcvzdjA2boy1XJNZXpfCZsxk3kEvKEMYELWvKClE3sUtnp9uuy6sD-t_2Ny78BH9F96A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71222395</pqid></control><display><type>article</type><title>Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine</title><source>MEDLINE</source><source>RePEc</source><source>SpringerLink Journals</source><creator>Hauber, A B ; Gnanasakthy, A ; Snyder, E H ; Bala, M V ; Richter, A ; Mauskopf, J A</creator><creatorcontrib>Hauber, A B ; Gnanasakthy, A ; Snyder, E H ; Bala, M V ; Richter, A ; Mauskopf, J A</creatorcontrib><description>To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation.
We assessed the relationship between Mini-Mental State Examination (MMSE) score and institutionalisation using a piecewise Cox proportional hazard model. To estimate cost savings from treatments lasting 6 months, 1 year and 2 years, estimates of the probability of institutionalisation were integrated with data from two 6-month phase III clinical trials of rivastigmine and a hazard model of disease progression.
Our data suggest that savings in the overall cost of caring for patients with mild and moderate AD can be as high as $US4839 per patient after 2 years of treatment. Furthermore, the probability of institutionalisation increases steadily as MMSE score falls. Among our study individuals, age, race, level of education and marital status were significant predictors of institutionalisation, whereas gender had little effect.
Using rivastigmine to treat AD results in a delay in disease progression for patients who begin treatment during the mild or moderate stages of the disease. By delaying the probability that a patient will be institutionalised, the cost of caring for AD patients can be significantly reduced.</description><identifier>ISSN: 1170-7690</identifier><identifier>EISSN: 1179-2027</identifier><identifier>DOI: 10.2165/00019053-200017040-00005</identifier><identifier>PMID: 10947490</identifier><language>eng</language><publisher>New Zealand: Springer Healthcare | Adis</publisher><subject>Aged ; Alzheimer Disease - classification ; Alzheimer Disease - drug therapy ; Alzheimer Disease - economics ; Alzheimer Disease - mortality ; Alzheimer's disease ; Carbamates - economics ; Carbamates - therapeutic use ; Cost analysis ; Cost Savings ; Economics, Pharmaceutical ; Female ; Health Care Costs - statistics & numerical data ; Health technology assessment ; Humans ; Institutionalization - economics ; Intelligence Tests ; Male ; Neuroprotective Agents - economics ; Neuroprotective Agents - therapeutic use ; Pharmacoeconomics ; Phenylcarbamates ; Probability ; Proportional Hazards Models ; Rivastigmine ; Severity of Illness Index ; Survival Rate</subject><ispartof>PharmacoEconomics, 2000-04, Vol.17 (4), p.351-360</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3994,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10947490$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/wkhphecon/v_3a17_3ay_3a2000_3ai_3a4_3ap_3a351-360.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>Hauber, A B</creatorcontrib><creatorcontrib>Gnanasakthy, A</creatorcontrib><creatorcontrib>Snyder, E H</creatorcontrib><creatorcontrib>Bala, M V</creatorcontrib><creatorcontrib>Richter, A</creatorcontrib><creatorcontrib>Mauskopf, J A</creatorcontrib><title>Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine</title><title>PharmacoEconomics</title><addtitle>Pharmacoeconomics</addtitle><description>To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation.
We assessed the relationship between Mini-Mental State Examination (MMSE) score and institutionalisation using a piecewise Cox proportional hazard model. To estimate cost savings from treatments lasting 6 months, 1 year and 2 years, estimates of the probability of institutionalisation were integrated with data from two 6-month phase III clinical trials of rivastigmine and a hazard model of disease progression.
Our data suggest that savings in the overall cost of caring for patients with mild and moderate AD can be as high as $US4839 per patient after 2 years of treatment. Furthermore, the probability of institutionalisation increases steadily as MMSE score falls. Among our study individuals, age, race, level of education and marital status were significant predictors of institutionalisation, whereas gender had little effect.
Using rivastigmine to treat AD results in a delay in disease progression for patients who begin treatment during the mild or moderate stages of the disease. By delaying the probability that a patient will be institutionalised, the cost of caring for AD patients can be significantly reduced.</description><subject>Aged</subject><subject>Alzheimer Disease - classification</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - economics</subject><subject>Alzheimer Disease - mortality</subject><subject>Alzheimer's disease</subject><subject>Carbamates - economics</subject><subject>Carbamates - therapeutic use</subject><subject>Cost analysis</subject><subject>Cost Savings</subject><subject>Economics, Pharmaceutical</subject><subject>Female</subject><subject>Health Care Costs - statistics & numerical data</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Institutionalization - economics</subject><subject>Intelligence Tests</subject><subject>Male</subject><subject>Neuroprotective Agents - economics</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Pharmacoeconomics</subject><subject>Phenylcarbamates</subject><subject>Probability</subject><subject>Proportional Hazards Models</subject><subject>Rivastigmine</subject><subject>Severity of Illness Index</subject><subject>Survival Rate</subject><issn>1170-7690</issn><issn>1179-2027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>X2L</sourceid><recordid>eNo9UEtLAzEYDKJoffwFyUlPq3lsNs1Rik8EPdSbsGSTb7vRfZmkLfrrTbV6mG-GYZgPBiFMyQWjhbgkhFBFBM_YRkmSkywJInbQhFKpks3k7o8mmSwUOUCHIbylRMEl20cHlKhc5opM0OvzEKGPTrc46JXrFwG7HscGsBlCxEONjfbJxvXg8VX71YDrwJ8HbF0AHeACzz3o2KUOvHaxwd6tdIhu0bkejtFerdsAJ1s-Qi831_PZXfb4dHs_u3rMRk5EzCpjqSWFnZqKC5iKSpFa5lLVFaemMLQyXFZcG1NXVkgppsoyVhRAubKW1oIfobPf3tEPH0sIsexcMNC2uodhGUpJGWNcbYIPv0EPI5hy9K7T_rNcvzdjA2boy1XJNZXpfCZsxk3kEvKEMYELWvKClE3sUtnp9uuy6sD-t_2Ny78BH9F96A</recordid><startdate>20000401</startdate><enddate>20000401</enddate><creator>Hauber, A B</creator><creator>Gnanasakthy, A</creator><creator>Snyder, E H</creator><creator>Bala, M V</creator><creator>Richter, A</creator><creator>Mauskopf, J A</creator><general>Springer Healthcare | Adis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>7X8</scope></search><sort><creationdate>20000401</creationdate><title>Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine</title><author>Hauber, A B ; Gnanasakthy, A ; Snyder, E H ; Bala, M V ; Richter, A ; Mauskopf, J A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p305t-bcd1d06d8cb35e85b90f7479fb31c6c1bc37b3accfbd577589d2266e139dd1f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Alzheimer Disease - classification</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - economics</topic><topic>Alzheimer Disease - mortality</topic><topic>Alzheimer's disease</topic><topic>Carbamates - economics</topic><topic>Carbamates - therapeutic use</topic><topic>Cost analysis</topic><topic>Cost Savings</topic><topic>Economics, Pharmaceutical</topic><topic>Female</topic><topic>Health Care Costs - statistics & numerical data</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Institutionalization - economics</topic><topic>Intelligence Tests</topic><topic>Male</topic><topic>Neuroprotective Agents - economics</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Pharmacoeconomics</topic><topic>Phenylcarbamates</topic><topic>Probability</topic><topic>Proportional Hazards Models</topic><topic>Rivastigmine</topic><topic>Severity of Illness Index</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hauber, A B</creatorcontrib><creatorcontrib>Gnanasakthy, A</creatorcontrib><creatorcontrib>Snyder, E H</creatorcontrib><creatorcontrib>Bala, M V</creatorcontrib><creatorcontrib>Richter, A</creatorcontrib><creatorcontrib>Mauskopf, J A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>MEDLINE - Academic</collection><jtitle>PharmacoEconomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hauber, A B</au><au>Gnanasakthy, A</au><au>Snyder, E H</au><au>Bala, M V</au><au>Richter, A</au><au>Mauskopf, J A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine</atitle><jtitle>PharmacoEconomics</jtitle><addtitle>Pharmacoeconomics</addtitle><date>2000-04-01</date><risdate>2000</risdate><volume>17</volume><issue>4</issue><spage>351</spage><epage>360</epage><pages>351-360</pages><issn>1170-7690</issn><eissn>1179-2027</eissn><abstract>To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation.
We assessed the relationship between Mini-Mental State Examination (MMSE) score and institutionalisation using a piecewise Cox proportional hazard model. To estimate cost savings from treatments lasting 6 months, 1 year and 2 years, estimates of the probability of institutionalisation were integrated with data from two 6-month phase III clinical trials of rivastigmine and a hazard model of disease progression.
Our data suggest that savings in the overall cost of caring for patients with mild and moderate AD can be as high as $US4839 per patient after 2 years of treatment. Furthermore, the probability of institutionalisation increases steadily as MMSE score falls. Among our study individuals, age, race, level of education and marital status were significant predictors of institutionalisation, whereas gender had little effect.
Using rivastigmine to treat AD results in a delay in disease progression for patients who begin treatment during the mild or moderate stages of the disease. By delaying the probability that a patient will be institutionalised, the cost of caring for AD patients can be significantly reduced.</abstract><cop>New Zealand</cop><pub>Springer Healthcare | Adis</pub><pmid>10947490</pmid><doi>10.2165/00019053-200017040-00005</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1170-7690 |
| ispartof | PharmacoEconomics, 2000-04, Vol.17 (4), p.351-360 |
| issn | 1170-7690 1179-2027 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71222395 |
| source | MEDLINE; RePEc; SpringerLink Journals |
| subjects | Aged Alzheimer Disease - classification Alzheimer Disease - drug therapy Alzheimer Disease - economics Alzheimer Disease - mortality Alzheimer's disease Carbamates - economics Carbamates - therapeutic use Cost analysis Cost Savings Economics, Pharmaceutical Female Health Care Costs - statistics & numerical data Health technology assessment Humans Institutionalization - economics Intelligence Tests Male Neuroprotective Agents - economics Neuroprotective Agents - therapeutic use Pharmacoeconomics Phenylcarbamates Probability Proportional Hazards Models Rivastigmine Severity of Illness Index Survival Rate |
| title | Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T03%3A53%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_repec&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20savings%20in%20the%20cost%20of%20caring%20for%20Alzheimer's%20disease.%20Treatment%20with%20rivastigmine&rft.jtitle=PharmacoEconomics&rft.au=Hauber,%20A%20B&rft.date=2000-04-01&rft.volume=17&rft.issue=4&rft.spage=351&rft.epage=360&rft.pages=351-360&rft.issn=1170-7690&rft.eissn=1179-2027&rft_id=info:doi/10.2165/00019053-200017040-00005&rft_dat=%3Cproquest_repec%3E71222395%3C/proquest_repec%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71222395&rft_id=info:pmid/10947490&rfr_iscdi=true |